NASDAQ : TARA
Protara Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.48 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 146.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 23.56M | 21.92M | 17.45M | 18.62M | 20.74M | 26.40M |
| Research & Development | 53.23M | 42.63M | 31.70M | 24.99M | 16.81M | 21.09M |
| Operating Expenses | 76.79M | 64.55M | 49.15M | 43.61M | 37.55M | 47.49M |
| Operating Income | -76.79M | -64.55M | -49.15M | -43.61M | -37.55M | -47.49M |
| Interest & Investment Income | 6.53M | 6.38M | 4.17M | 3.19M | 1.11M | 237.00K |
| Other Non Operating Income (Expenses) | 249.00K | 730.00K | 387.00K | |||
| EBT Excluding Unusual Items | -70.02M | -57.44M | -44.60M | -40.42M | -36.44M | -47.25M |
| Impairment of Goodwill | -29.52M | |||||
| Pretax Income | -70.02M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Net Income | -70.02M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Net Income to Common | -70.02M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Shares Outstanding (Basic) | 51.73M | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M |
| Shares Outstanding (Diluted) | 51.73M | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M |
| EPS (Basic) | -1.35 | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 |
| EPS (Diluted) | -1.35 | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 |
| Free Cash Flow | -66.49M | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Free Cash Flow Per Share | -1.28 | -1.32 | -1.74 | -3.32 | -2.36 | -3.12 |
| EBITDA | -76.45M | -64.19M | -48.82M | -43.27M | -37.30M | -47.37M |
| D&A For EBITDA | 343.00K | 362.00K | 332.00K | 341.00K | 248.00K | 117.00K |
| EBIT | -76.79M | -64.55M | -49.15M | -43.61M | -37.55M | -47.49M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 17.08M | 49.66M | 162.80M | 39.59M | 24.13M | 35.72M |
| Short-Term Investments | 125.42M | 105.90M | 7.49M | 25.99M | 60.24M | 55.51M |
| Cash & Short-Term Investments | 142.49M | 155.55M | 170.29M | 65.58M | 84.37M | 91.23M |
| Other Receivables | 1.28M | 1.26M | 242.00K | 486.00K | 634.00K | |
| Receivables | 1.28M | 1.26M | 242.00K | 486.00K | 634.00K | |
| Prepaid Expenses | 660.00K | 702.00K | 928.00K | 889.00K | 594.00K | 531.00K |
| Other Current Assets | 1.72M | 1.99M | 935.00K | 1.99M | 696.00K | 718.00K |
| Total Current Assets | 146.15M | 159.50M | 172.16M | 68.70M | 86.15M | 93.11M |
| Property, Plant & Equipment | 3.92M | 3.93M | 5.28M | 6.56M | 7.87M | 8.89M |
| Long-Term Investments | 19.36M | 42.34M | 17.89M | 39.47M | ||
| Goodwill | 29.52M | |||||
| Long-Term Deferred Charges | 5.85M | 2.93M | 3.25M | 2.66M | 84.00K | |
| Other Long-Term Assets | 819.00K | 765.00K | 772.00K | 1.03M | 1.30M | 1.61M |
| Total Assets | 176.09M | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Accounts Payable | 4.66M | 3.47M | 4.43M | 2.43M | 1.59M | 954.00K |
| Accrued Expenses | 7.37M | 6.23M | 5.41M | 2.73M | 3.24M | 2.49M |
| Current Portion of Leases | 1.29M | 1.24M | 1.12M | 983.00K | 917.00K | 855.00K |
| Total Current Liabilities | 13.32M | 10.94M | 10.96M | 6.15M | 5.74M | 4.30M |
| Long-Term Leases | 1.46M | 2.12M | 3.36M | 4.48M | 5.47M | 6.38M |
| Total Liabilities | 14.78M | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Common Stock | 59.00K | 54.00K | 35.00K | 11.00K | 11.00K | 11.00K |
| Additional Paid-In Capital | 503.48M | 498.69M | 412.08M | 268.73M | 262.72M | 256.13M |
| Retained Earnings | -341.87M | -302.42M | -244.98M | -200.38M | -159.96M | -94.01M |
| Comprehensive Income & Other | -363.00K | 90.00K | 2.00K | -31.00K | -688.00K | -211.00K |
| Shareholders' Equity | 161.31M | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
| Total Liabilities & Equity | 176.09M | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Total Debt | 2.75M | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Net Cash (Debt) | 159.10M | 194.53M | 165.81M | 60.11M | 95.87M | 123.46M |
| Net Cash Per Share | 3.08 | 4.54 | 8.05 | 5.31 | 8.51 | 10.99 |
| Filing Date Shares Outstanding | 59.10M | 54.08M | 36.77M | 11.43M | 11.31M | 11.25M |
| Total Common Shares Outstanding | 59.08M | 53.59M | 35.04M | 11.36M | 11.27M | 11.24M |
| Working Capital | 132.83M | 148.56M | 161.19M | 62.56M | 80.41M | 88.81M |
| Book Value Per Share | 2.73 | 3.67 | 4.77 | 6.01 | 9.06 | 14.41 |
| Tangible Book Value | 161.31M | 196.41M | 167.13M | 68.32M | 102.08M | 132.40M |
| Tangible Book Value Per Share | 2.73 | 3.67 | 4.77 | 6.01 | 9.06 | 11.78 |
| Machinery | 1.67M | 1.50M | 1.51M | 1.42M | 1.12M | |
| Leasehold Improvements | 553.00K | 553.00K | 553.00K | 553.00K | 224.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -70.02M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Depreciation & Amortization | 343.00K | 362.00K | 332.00K | 341.00K | 248.00K | 117.00K |
| Asset Writedown & Restructuring Costs | 29.52M | |||||
| Loss (Gain) From Sale of Investments | -1.08M | -1.25M | -685.00K | -444.00K | 1.14M | 1.74M |
| Stock-Based Compensation | 4.84M | 3.83M | 4.12M | 6.09M | 6.69M | 10.36M |
| Other Operating Activities | 1.12M | 1.08M | 1.01M | 1.01M | 1.37M | 1.05M |
| Change in Accounts Payable | -1.02M | -873.00K | 1.38M | 848.00K | 631.00K | 40.00K |
| Change in Other Net Operating Assets | -315.00K | -2.07M | 2.63M | -4.99M | -92.00K | -556.00K |
| Operating Cash Flow | -66.13M | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Capital Expenditures | -360.00K | -94.00K | -63.00K | -45.00K | -120.00K | -596.00K |
| Investment in Securities | -30.02M | -139.40M | 19.22M | 53.15M | 15.07M | -97.60M |
| Investing Cash Flow | -30.38M | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Issuance of Common Stock | 82.92M | 83.73M | 149.03M | |||
| Repurchase of Common Stock | -298.00K | -185.00K | -83.00K | -91.00K | -90.00K | -228.00K |
| Other Financing Activities | -526.00K | -828.00K | -9.09M | |||
| Financing Cash Flow | 82.09M | 82.72M | 139.87M | -91.00K | -90.00K | -228.00K |
| Net Cash Flow | -14.42M | -113.14M | 123.21M | 15.46M | -11.60M | -132.92M |
| Free Cash Flow | -66.49M | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Free Cash Flow Per Share | -1.28 | -1.32 | -1.74 | -3.32 | -2.36 | -3.12 |
| Levered Free Cash Flow | -40.49M | -38.48M | -20.39M | -21.88M | -15.16M | -20.23M |
| Unlevered Free Cash Flow | -40.49M | -38.48M | -20.39M | -21.88M | -15.16M | -20.23M |
| Change in Working Capital | -1.34M | -2.94M | 4.01M | -4.14M | 539.00K | -516.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 142.42M | 285.62M | 253.49M | 21.31M | 30.20M | 75.84M |
| Enterprise Value | -16.68M | 155.65M | 176.73M | -47.02M | -70.28M | -55.13M |
| Last Close Price | 2.48 | 5.33 | 5.28 | 1.88 | 2.68 | 6.75 |
| PB Ratio | 0.91 | 1.45 | 1.52 | 0.31 | 0.30 | 0.47 |
| P/TBV Ratio | 0.92 | 1.45 | 1.52 | 0.31 | 0.30 | 0.57 |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.03 | 0.08 | 0.06 | 0.04 |
| Net Debt / Equity Ratio | -0.99 | -0.99 | -0.99 | -0.88 | -0.94 | -0.76 |
| Net Debt / EBITDA Ratio | 2.08 | 3.03 | 3.40 | 1.39 | 2.57 | 2.61 |
| Net Debt / FCF Ratio | 2.39 | 3.45 | 4.62 | 1.60 | 3.61 | 3.52 |
| Quick Ratio | 10.79 | 14.34 | 15.54 | 10.71 | 14.78 | 21.37 |
| Current Ratio | 10.97 | 14.58 | 15.71 | 11.17 | 15.01 | 21.66 |
| Return on Equity (ROE) | -45.80% | -31.60% | -37.88% | -47.44% | -49.96% | -26.17% |
| Return on Assets (ROA) | -28.82% | -20.64% | -23.59% | -28.36% | -16.42% | -15.80% |
| Return on Capital Employed (ROCE) | -47.20% | -32.50% | -28.80% | -59.90% | -34.90% | -28.20% |
| Earnings Yield | -56.16% | -20.11% | -17.59% | -189.67% | -218.41% | -62.30% |
| FCF Yield | -45.01% | -19.77% | -14.15% | -176.45% | -88.01% | -46.28% |
| Buyback Yield / Dilution | -55.93% | -108.02% | -81.73% | -0.64% | -0.24% | -55.28% |